Skip to main content

Tekmira Gets FDA Nod for Human Testing of Ebola Drug

Premium

Tekmira Pharmaceuticals this week announced that it has received clearance from the US Food and Drug Administration to begin human testing of an RNAi-based treatment for Ebola virus infection.

The drug, TKM-Ebola, was added to Tekmira's pipeline last summer after the company reported data showing that a cocktail of modified siRNAs targeting the Zaire Ebola virus L polymerase, viral protein 24, and viral protein 35 could completely protect non-human primates from a lethal dose of the virus when delivered using proprietary lipid nanoparticles (GSN 8/19/2010).

Tekmira, which is developing TKM-Ebola with the support of a $140 million contract from the US government, expects to begin a phase I trial in early 2012.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.